Enhanced Antitumor Efficacy of PhAc-ALGP-Dox, an Enzyme-Activated Doxorubicin Prodrug, in a Panel of THOP1-Expressing Patient-Derived Xenografts of Soft Tissue Sarcoma

Despite poor response rates and dose-limiting cardiotoxicity, doxorubicin (doxo) remains the standard-of-care for patients with advanced soft tissue sarcoma. We evaluated the efficacy of two tetrapeptidic doxo prodrugs (PhAc-ALGP-Dox or CBR-049 and CBR-050) that are locally activated by enzymes expr...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Renterghem, Britt, Wozniak, Agnieszka, Tarantola, Ludovica, Casazza, Andrea, Wellens, Jasmien, Nysen, Madita, Vanleeuw, Ulla, Lee, Che-Jui, Reyns, Geert, Sciot, Raf, Kindt, Nele, Schöffski, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025547/
https://www.ncbi.nlm.nih.gov/pubmed/35453612
http://dx.doi.org/10.3390/biomedicines10040862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025547/
https://www.ncbi.nlm.nih.gov/pubmed/35453612
http://dx.doi.org/10.3390/biomedicines10040862

Ejemplares similares